Autolus Therapeutics Financials - Benzinga

Autolus Therapeutics PLC

AUTLNASDAQ

Trade with Public

Trade with Public

$2.07

-0.04-1.9%

At close: Aug 10, 5:00 PM EST

$2.07

N/A

After Hours: 4:42 PM EST

Earnings: Q2 2026 earnings tomorrow on Tue Aug 11th before the market open

Conference Call: Conference call scheduled tomorrow at 8:30 AM

Click to view the webcast

Overview News Earnings Forecast Events Price TargetsFinancialsSentiment Compare Options Stock Report

Autolus Therapeutics Financials

Autolus Therapeutics (AUTL) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Autolus Therapeutics Sees FY2026 Sales $120.000M-$135.000M vs $130.062M Est

Autolus Therapeutics (NASDAQ:AUTL) sees FY2026 sales of $120.000 million-$135.000 million vs $130.062 million analyst estimate.

Benzinga Newsdesk

PRO
Autolus Therapeutics Q1 EPS $(0.27), Inline, Sales $26.218M Beat $26.160M Estimate

Autolus Therapeutics (NASDAQ:AUTL) reported quarterly losses of $(0.27) per share which met the analyst consensus estimate. This is a 3.85 percent decrease over losses of $(0.26) per share from the same period last year.

Benzinga Newsdesk

Earnings Scheduled For May 14, 2026

Benzinga Insights

Earnings Scheduled For March 27, 2026

Benzinga Insights

PRO
Autolus Therapeutics Q4 EPS $(0.34) Misses $(0.24) Estimate, Sales $24.289M Miss $24.481M Estimate

Autolus Therapeutics (NASDAQ:AUTL) reported quarterly losses of $(0.34) per share which missed the analyst consensus estimate of $(0.24) by 41.08 percent. This is a 277.78 percent decrease over losses of $(0.09) per

Benzinga Newsdesk

PRO
Autolus Therapeutics Q3 EPS $(0.30) Misses $(0.22) Estimate, Sales $21.194M Miss $21.311M Estimate

Autolus Therapeutics (NASDAQ:AUTL) reported quarterly losses of $(0.30) per share which missed the analyst consensus estimate of $(0.22) by 36.99 percent. This is a 3.23 percent increase over losses of $(0.31) per share

Benzinga Newsdesk